RCKT ROCKET PHARMACEUTICALS, INC.

RCKT financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1281895 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 12, 2026 Data checked: Nov 13, 2026
Showing 3 of 12 annual and 0 of 51 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$212.50M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
646-440-9100
EIN
000000000
Headquarters
NEW YORK, NY, 10118
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: INOTEK PHARMACEUTICALS CORP (2004–2017)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$0
Net Income
$-16.15M
Total Assets
$419.50M
Total Equity
$326.72M
Total Debt
$30.43M
Free Cash Flow
-
Ratios
Return on Equity
-4.9%
Return on Assets
-3.9%
Current Ratio
7.26x
Debt / Equity
0.09x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, ROCKET PHARMACEUTICALS, INC. recorded $0.00 of revenue, net loss of $223.12M, and an operating cash outflow of $190.01M. Diluted earnings per share were -$2.01, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 111.12M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 94.81M diluted shares in fiscal 2024, the current 111.12M base was 17.2% higher. The company employed $330.45M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

Operations produced a $231.75M operating loss before non-operating and tax effects. After all below-operating-line items, the company recorded a net loss of $223.12M for the fiscal year. Negative EBITDA totaled $222.85M, confirming that the earnings deficit remained before depreciation and amortization. Before income taxes, the company recorded a loss of $223.12M, bridging the operating result to the final net loss. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 80.5%, placing the bottom-line deficit against shareholder capital. The loss-to-assets relationship was 67.5%, placing the bottom-line deficit against the company’s resource base. The net loss narrowed to $223.12M from $258.75M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $330.45M asset base was financed through $53.23M of liabilities and $277.22M of equity. Current assets were $192.73M against $30.21M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered current liabilities by 6.38x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $77.56M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 256.8%, excluding receivables and other current assets. The equity-to-assets relationship was 83.9%, placing book capital against the total resource base. Relative to total assets, liabilities measured 16.1%, complementing the separate equity-based view of the company’s capital structure. The cash-to-assets relationship was 23.5%, comparing reported cash and equivalents with the full positive asset balance. Compared with $527.70M in fiscal 2024, the current asset base moved 37.4% and finished lower. Against $463.23M of equity in fiscal 2024, the current book-equity balance moved 40.2% and ended lower. Cash and equivalents were 52.6% lower than fiscal 2024 cash of $163.63M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

The company reported an operating cash outflow of $190.01M, rather than cash generation from operations. Capital expenditures used $440.00K in addition to the operating cash outflow, increasing the total cash consumed by operations and investment during the period. Negative free cash flow was $190.45M, leaving a cash deficit after capital spending and reducing financial flexibility. The cash deficit after capital spending represented 57.6% of the period-end asset base. Compared with a $209.72M operating cash outflow in fiscal 2024, the current outflow improved to $190.01M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for ROCKET PHARMACEUTICALS, INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $0 $0 $0
OPERATING EXPENSES
R&D Expense $142.02M $171.24M $186.34M
SG&A Expense $86.50M $101.96M $73.32M
Operating Income $-231.75M $-273.21M $-259.66M
NON-OPERATING INCOME / EXPENSE
Interest Expense $1.89M $1.89M $1.88M
Pretax Income $-223.12M $-258.75M -
Income Tax $0 $0 $0
Net Income $-223.12M $-258.75M $-245.60M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-2.01 $-2.73 $-2.92
Diluted Shares 111.12M 94.81M 84.01M
EBITDA $-222.85M $-266.01M $-254.76M
Depreciation & Amortization $8.90M $7.20M $4.90M
Balance Sheet
ASSETS
Cash & Equivalents $77.56M $163.64M $55.90M
Short-term Investments $111.37M $208.70M $317.27M
Other Current Assets $3.81M $5.85M $5.05M
Current Assets $192.73M $378.18M $378.22M
PP&E (Net) $28.17M $36.79M $39.17M
Goodwill $39.15M $39.15M $39.15M
Intangible Assets $25.15M $25.15M $25.15M
Other Noncurrent Assets (derived) $45.24M $48.43M $84.64M
Noncurrent Assets $137.72M $149.52M $188.12M
Total Assets $330.45M $527.70M $566.34M
LIABILITIES
Accounts Payable $27.29M $37.83M $45.79M
Other Current Liabilities $2.33M $1.63M $1.77M
Current Liabilities $30.21M $40.68M $48.51M
Other Noncurrent Liabilities $1.06M $1.14M $2.94M
Noncurrent Liabilities $23.02M $23.78M $25.26M
Total Liabilities $53.23M $64.47M $73.77M
EQUITY
Common Stock $1.08M $1.07M $903.00K
Additional Paid-in Capital $1.72B $1.68B $1.45B
Retained Earnings $-1.44B $-1.22B $-959.37M
Accumulated OCI $-31.00K $66.00K $319.00K
Total Equity $277.22M $463.23M $492.57M
Total Liabilities & Equity $330.45M $527.70M $566.34M
SUPPLEMENTAL
Shares Outstanding 108.32M 106.45M 90.28M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-190.01M $-209.72M $-194.92M
Capital Expenditures $440.00K $5.86M $16.44M
Cash from Investing $103.77M $131.71M $-98.07M
Cash from Financing $148.00K $185.74M $208.40M
Free Cash Flow $-190.45M $-215.59M $-211.35M
Beginning Cash (CFS) $165.00M $57.28M $141.86M
Net Change in Cash $-86.10M $107.72M $-84.58M
Effect of FX on Cash - - -
Calculated Ending Cash $78.90M $165.00M $57.28M
Cash per BS $77.56M $163.64M $55.90M
Cash scope difference (CFS − BS) $1.34M $1.36M $1.37M
Cash per CFS $78.90M $165.00M $57.28M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is ROCKET PHARMACEUTICALS, INC.'s annual revenue?

ROCKET PHARMACEUTICALS, INC. reported $0 in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is ROCKET PHARMACEUTICALS, INC. profitable?

No. ROCKET PHARMACEUTICALS, INC. reported $-16.15M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

What is ROCKET PHARMACEUTICALS, INC.'s debt level?

ROCKET PHARMACEUTICALS, INC. carries $30.43M in total debt as of trailing twelve months. Total shareholders' equity stands at $326.72M.